---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-000218"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2023-01-04T23:59:59+00:00"
generated_at: "2026-06-20T20:24:15.241056+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Reviva reports 40% enrollment in Phase 3 schizophrenia trial; top-line data expected mid-2023

## Summary
- About 40% of patients treated in pivotal Phase 3 RECOVER trial of brilaroxazine; no treatment-related SAEs.
- Top-line data from Phase 3 trial expected mid-2023; NDA submission planned if positive, potential commercial launch in 2025.
- Completed DDI study for brilaroxazine; results indicate advantage over other antipsychotics regarding drug interactions.
- Raised $8.5M in September 2022 from registered direct offering and private placement; improved financial position.
- Exploring non-dilutive financing and partnerships to expand brilaroxazine into bipolar, MDD, ADHD, PAH, IPF; combined market >$70B.

## SEC filing metadata
- accession: 0001437749-23-000218
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2023-01-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774923000218/0001437749-23-000218-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774923000218/rvph20230102_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-000218
- JSON: https://secwatch.observer/filing/0001437749-23-000218.json
- Plain text: https://secwatch.observer/filing/0001437749-23-000218.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.